Senolytics New Material to Eliminate Senescent Cells Japan Pharmaceutical Medicine Co., Ltd. releases information on "SENOX25(TM)".

~GLS1 enzyme targeting food field applications, patent pending~.

2025.06.30 09:00

日本医療製薬株式会社

Japan Pharmaceutical Medicine Co., Ltd.(President: Kumiko Hayakawa) has discovered a new substance "SENOX25(TM)" (scientific name: Pleurotus citrinopileatus) as a senolytic material that selectively eliminates aging cells, and filed a patent application in December 2024, which is currently pending. We are pleased to announce that information on this novel substance "SENOX25(TM)" is now available to the public.

In this research, SENOX25(TM) was found to inhibit the expression of the GLS-1 gene, which is associated with aging-related diseases, in a concentration-dependent manner, and is expected to be utilized as an anti-aging and healthy life extension material in the future.

SENOX25(TM) has been shown to selectively affect senescent cells through genetic research using human cells.

SENOX25(TM) is a safe mushroom-derived ingredient that has been consumed for centuries, and embodies the concept of "eating for health" rather than relying on pharmaceuticals.

Currently, there is a gap of about 10 years between the average life expectancy of Japanese people and their healthy life expectancy. We are focusing our research efforts on narrowing this gap and are currently developing a dietary supplement containing SENOX25(TM).

Representative Hayakawa founded the company with the idea of pursuing materials that can care for the body by eating, rather than by medicine. Researchers belonging to Nippon Medical & Pharmaceuticals have continued their research on aging cells for many years in collaboration with specialists in many fields. As a result, they discovered that SENOX25(TM) may contribute to the selective elimination of senescent cells, leading to the filing of a patent application.

SENOX25(TM) has an integrated quality control system from cultivation to processing and commercialization under our own management, and we are now looking into the application of SENOX25(TM) as a functional food and a dietary supplement.

Our wish is that everyone can live a healthy and active life throughout his or her life. We will continue our research earnestly to help realize this goal.

About the research results

Inhibition of GLS-1 gene expression

Senescent cells discharge various substances that are harmful to the living body by surviving.

It has long been known that GLS1 converts glutamine to glutamic acid, which produces ammonia along with metabolites important for energy metabolism. It has been shown that senescent cells can maintain their survival by regulating intracellular pH homeostasis by producing excess ammonia by increasing the amount of GLS1 as the intracellular pH decreases. This is the mechanism by which senescent cells try to survive.

*GLS-1 gene expression analysis results

SENOX25(TM) was found to inhibit GLS-1 gene expression in a concentration-dependent manner.

This suggests that SENOX25(TM) is effective in preventing senescent cells (zombie cells) from surviving in vain and having a negative effect on the living body.

SENOX25(TM)と試験データ